Skip to main content
Premium Trial:

Request an Annual Quote

Simulations Plus Acquires Bioreason for $788K

, Nov. 11 (GenomeWeb News) - Simulations Plus has acquired all assets of Santa Fe, NM-based cheminformatics firm Bioreason in an all-cash transaction worth approximately $788,000.


Through the transaction, Simulations Plus acquired software, source code, two patents, trademarks, marketing and sales information, and all other fixed assets.


Simulations Plus said that Bioreason's flagship software, ClassPharmer will be integrated into a single product with Sage Informatics ChemTK package.


ClassPharmer is currently licensed to over 30 companies in the US, Europe, and Japan.


Momoko Beran, chief financial officer of Simulations Plus, said in a statement that Bioreason's assets include nearly $400,000 in accounts receivable from multi-year licenses, "with some of these due as early as this month. Most companies license on an annual basis, and if all licenses that will expire during this fiscal year are renewed, revenues from such licenses would exceed $500,000."


This article originally appeared in BioInform, a GenomeWeb News sister publication.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.